Detail

Gadoteridol

Description

Name: Gadoteridol
Type: small molecule
Groups: approved
Indication: Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Accession Number: DB00597 ( APRD00992)
Description: Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Prohanceinjection, solution279.3 mg/mLintravenous16-11-1992US
Prohance - Liq IV 279.3mg/mlsolution279.3 mgintravenous08-09-1998Canada
Prohance Liq IV 279.3mg/mlliquid279.3 mgintravenous31-12-199330-07-1998Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
ProhanceGadoteridol
Prohance - Liq IV 279.3mg/mlGadoteridol
Prohance Liq IV 279.3mg/mlGadoteridol

Categories
  • Contrast Media

Pharmacology

Indication: Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Gadoteridol does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Absorption: Not Available
Volume of distribution:
  • 204 ± 58 mL/kg

Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Gadoteridol is eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post-injection.
Half life: Distribution 12 minutes (mean), elimination 100 minutes (mean).
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Bracco diagnostics inc

Packagers:
Dosage forms
FormRouteStrength
Injection, solutionintravenous279.3 mg/mL
Solutionintravenous279.3 mg
Liquidintravenous279.3 mg

Prices
Unit descriptionCostUnit
Prohance 279.3 mg/ml vial$6.81ml

Patents
CountryPatent NumberApprovedExpires (estimated)
1341176Canada2001-01-302018-01-30
5474756United States1992-12-122012-12-12
5846519United States1995-12-082015-12-08

Interactions

Drug Interactions
DrugInteraction

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • 1,2-aminoalcohols
  • Azacyclic compounds
  • Carbonyl compounds
  • Carboxylic acid salts
  • Carboxylic acids
  • Hydrocarbon derivatives
  • Organic salts
  • Organic zwitterions
  • Secondary alcohols
  • Trialkylamines
  • Tricarboxylic acids and derivatives

substituent:
  • 1,2-aminoalcohol
  • Alcohol
  • Aliphatic heteromonocyclic compound
  • Alpha-amino acid
  • Amine
  • Azacycle
  • Carbonyl group
  • Carboxylic acid
  • Carboxylic acid salt
  • Hydrocarbon derivative
  • Organic salt
  • Organic zwitterion
  • Organoheterocyclic compound
  • Organonitrogen compound
  • Organooxygen compound
  • Secondary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Tricarboxylic acid or derivatives

References

Synthesis Reference: Not Available
General Reference: Not Available
External Links:
ResourceLink

ATC Codes:
  • Array

AHFS Codes:
  • 92:00.00

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?